BioCentury
ARTICLE | Finance

Friendly persuasion

Quaker BioVentures brokers merger of Arginetix, Immune Control

June 21, 2010 7:00 AM UTC

Arginetix Inc. and Immune Control Inc. agreed to merge last week in a union officiated by Quaker BioVentures, which saw an opportunity to combine a pair of early-stage portfolio companies in the same space.

Gary Lessing, who had been CEO at Arginetix and who retains the same title at the newco, Corridor Pharmaceuticals Inc., told Ebb & Flow that "we were two virtual companies, each running a single program, each with a small set of venture investors, both going after pulmonary and vascular indications."...